Search
Research
Improving delivery of secondary prophylaxis for rheumatic heart disease in remote Indigenous communitiesThis trial aims to improve uptake of secondary prophylaxis among Aboriginal people with ARF/RHD to reduce progression or worsening of RHD.
Research
Strep A: challenges, opportunities, vaccine-based solutions and economicsStreptococcus pyogenes (Strep A) is a leading cause of morbidity and mortality across the globe, annually causing hundreds of millions of cases of disease.
Research
Impact of mitral regurgitation on left ventricular remodeling and function in children with rheumatic heart diseaseThe impact of mitral regurgitation from pediatric rheumatic heart disease and its effect on left ventricular remodeling and function following surgical intervention is uncertain. The objective is to explore the impact of mitral valve surgeries on myocardial mechanics, remodeling and function and identify pre-operative predictors of post-operative dysfunction which may contribute to the optimal timing of intervention.
Research
Population-based assessment of cardiovascular complications of rheumatic heart disease in Fiji: a record-linkage analysisTo determine population-based rates of non-fatal complications of rheumatic heart disease (RHD).
Research
The economic and health burdens of diseases caused by group A Streptococcus in New ZealandIn preparation for the future arrival of a group A Streptococcus (GAS) vaccine, this study estimated the economic and health burdens of GAS diseases in New Zealand. The annual incidence of GAS diseases was based on extrapolation of the average number of primary healthcare episodes managed each year in general practices (2014-2016) and on the average number of hospitalizations occurring each year (2005-2014). Disease incidence was multiplied by the average cost of diagnosing and managing an episode of disease at each level of care to estimate the annual economic burden.
Research
Structured review of primary interventions to reduce group A streptococcal infections, acute rheumatic fever and rheumatic heart diseaseRheumatic heart disease (RHD) is a large, preventable, global public health burden. In New Zealand (NZ), acute rheumatic fever (ARF) and RHD rates are highest for Māori and Pacific children. This structured review explores the evidence for primary prevention interventions to diagnose and effectively treat group A Streptococcus (GAS) pharyngitis and skin infections to reduce rates of ARF and RHD.
Research
Standardizing clinical care measures of rheumatic heart disease in pregnancy: A qualitative synthesisPregnancy provides an opportunity to strengthen health system responses and address whole-of-life health for women with rheumatic heart disease
Research
Rheumatic heart disease in pregnancy: How can health services adapt to the needs of Indigenous women? A qualitative studyHealth systems did not meet the needs of pregnant Aboriginal women with rheumatic heart disease
Research
Primary prevention of rheumatic fever in the 21st century: evaluation of a national programmePopulation-based primary prevention of ARF through sore throat management may be effective in well-resourced settings like New Zealand
Research
Acute rheumatic feverAcute rheumatic fever is an autoimmune disorder resulting from Group A Streptococcus pharyngitis or impetigo in children and adolescents, which may evolve to rheumatic heart disease (RHD) with persistent cardiac valve damage. RHD causes substantial mortality and morbidity globally, predominantly among socioeconomically disadvantaged populations, with an interplay of social determinants of health and genetic factors determining overall risk.